Publish date:

Verdict Boosts Amgen

Roche won't be allowed to sell Mircera, its rival medicine to Amgen's Aranesp and Epogen, in the U.S.

A jury voted in favor of

Amgen

(AMGN) - Get Report

Tuesday in a patent dispute case, according to a

Bloomberg

TheStreet Recommends

report.

The ruling determines in effect that

Roche

may not sell Mircera, its rival medicine to Amgen's Aranesp and Epogen anemia drugs, in the U.S.

Amgen shares were rising 87 cents, or 1.6%, to $56.99 in recent trading.